GSK insiders add ADS via dividend reinvestment

GSK plc reported routine insider share transactions for two senior figures under its executive savings plans.

Rhea-AI Filing Summary

GSK plc reported routine insider share transactions for two senior figures under its executive savings plans. Non-Executive Director Dr Hal Barron acquired 2,007.552 notional American Depositary Shares at $59.5200 per ADS on 20 February 2026 through automatic dividend reinvestment.

On the same date, James Ford, SVP and Group General Counsel, acquired 47.460 notional ADS, also at $59.5200 per ADS, via dividend reinvestment in his GSK Executive Supplemental Savings Plan account. Both transactions took place on the New York Stock Exchange.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GSK (GSK) report in this Form 6-K?

GSK reported two routine insider acquisitions of notional American Depositary Shares through dividend reinvestment in executive savings plans. Both transactions occurred on 20 February 2026 on the New York Stock Exchange and reflect plan-related activity, not open-market discretionary buying.

How many GSK ADS did Dr Hal Barron acquire and at what price?

Dr Hal Barron acquired 2,007.552 notional GSK American Depositary Shares at a price of $59.5200 per ADS. The acquisition occurred via dividend reinvestment within his GSK Executive Supplemental Savings Plan account on 20 February 2026 on the New York Stock Exchange.

What shares did GSK SVP James Ford acquire in the reported transaction?

James Ford acquired 47.460 notional GSK American Depositary Shares at a price of $59.5200 per ADS. This was an automatic reinvestment of dividends in his GSK Executive Supplemental Savings Plan account, executed on 20 February 2026 on the New York Stock Exchange.

Were the GSK insider transactions open-market purchases or plan reinvestments?

Both GSK insider transactions were plan-based reinvestments, not discretionary open-market purchases. The filing specifies they were acquisitions of notional ADS within GSK Executive Supplemental Savings Plan accounts following the reinvestment of dividends, executed on the New York Stock Exchange.

Which financial instrument was involved in the GSK insider acquisitions?

The transactions involved GSK American Depositary Shares, identified with ISIN US37733W2044. These ADS represent GSK plc equity traded on the New York Stock Exchange and were acquired notionally through dividend reinvestment in executive supplemental savings plans for the two senior personnel.

On what date did the GSK insider dividend reinvestment transactions occur?

Both insider dividend reinvestment transactions occurred on 20 February 2026. On that date, notional GSK American Depositary Shares were acquired within the GSK Executive Supplemental Savings Plan accounts for Dr Hal Barron and James Ford, with trades executed on the New York Stock Exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 11:16 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.5200	2,007.552
			d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-02-20
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.5200	47.460
			d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-02-20
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 24, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc